FindTrial
Sign In

Human epididymis protein 4 combined with creatinine used to identify ovarian tumors and chronic nephropathy

Human epididymis protein 4 combined with creatinine used to identify ovarian tumors and chronic nephropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018386
Enrollment
Unknown
Registered
2018-09-14
Start date
2018-09-17
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian tumor

Interventions

Gold Standard:Pathological diagnosis, clinical diagnosis
Index test:Human&#32
epididymis&#32
protein&#32
4,&#32
creatinine

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Histopathologically diagnosed as an ovarian tumor; 2. Clinical diagnosis of chronic nephropathy patients; 3. The healthy control group is the physical examination group without the individual of the existing disease

Exclusion criteria

Exclusion criteria: 1. Combined with other systems of primary malignancies; 2. Complicated with myocardial infarction, diabetes and other serious vascular disease patients, long-term smoking patients, cardiovascular, rheumatic, infection, pregnancy patients.

Design outcomes

Primary

MeasureTime frame
Human epididymis protein 4;creatinine;—

Countries

China

Contacts

Public ContactFan Quming

Affiliated Hospital of North Sichuan Medical College

fanqum@163.com+86 13550592716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026